ACARD 300 mg, 300 mg, tabletki, Microcrystalline cellulose, Native corn starch, Citric acid anhydrous (E330)
AERD-COV19
Phase 3 small_molecule active
Quick answer
ACARD 300 mg, 300 mg, tabletki, Microcrystalline cellulose, Native corn starch, Citric acid anhydrous (E330) for aspirin-exacerbated respiratory disease is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- COLLEGIUM PHARMACEUTICAL, INC
- Indication
- aspirin-exacerbated respiratory disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active